DocWire News Editors

DocwireNews

In a study recently published in Circulation, researchers set out to find patterns of apixaban use and associated outcomes in end-stage kidney disease (ESKD) patients who are dependent on dialysis and have atrial fibrillation (AF). Information from the United States Renal Data System on 25,523 dialysis-dependent patients with ESKD and AF who received oral anticoagulant treatment was used in a retrospective cohort study of Medicare beneficiaries. Researchers originally wanted to investigate dabigatran and rivaroxaban users, however due to the limited number of users they assessed patients who used apixaban or warfarin instead. Major bleeding, survival free of stroke or systemic embolism, intracranial bleeding, death, and gastrointestinal were assessed as outcomes of interest.After matching the two cohorts, researchers found that there was no significant difference in risks of stroke or systemic embolism between the apixaban and warfarin users. They did, however, find that apixaban users had significantly lower risks of major bleeding. In addition, those who took a standard daily dose of apixaban (5 mg twice a day) displayed significantly lower risks of stroke, systemic embolism, and death than those taking the lower dosage or warfarin.Researchers concluded in comparison to warfarin, apixaban may be linked to lower risks of major bleeding in dialysis-dependent EKSD patients with AF, and that taking 5mg twice daily may reduce mortality and thromboembolic risks.Source:&nbsp;<a href="http://circ.ahajournals.org/content/early/2018/06/22/CIRCULATIONAHA.118.035418">Circulation</a>

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

Comparison of Anticoagulant Effects in Kidney Disease Patients with Atrial Fibrillation

Atrial Fibrillation

In a study recently published in Circulation, researchers set out to find patterns of apixaban use and associated outcomes in end-stage kidney disease (ESKD) patients who are ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe